Compile Data Set for Download or QSAR
maximum 50k data
Found 672 with Last Name = 'terstiege' and Initial = 'i'
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599226(CHEMBL5201062 | US11866405, Example 100)
Affinity DataIC50: <0.0300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599222(CHEMBL5190644 | US11866405, Example 12)
Affinity DataIC50:  0.100nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599223(CHEMBL5202941 | US11866405, Example 23)
Affinity DataIC50:  0.200nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643825(US11866405, Example 95)
Affinity DataIC50:  0.200nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643809(US11866405, Example 87)
Affinity DataIC50:  0.200nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643867(US11866405, Example 116)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50599227(CHEMBL5204583 | US11866405, Example 117)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643875(US11866405, Example 120 | US11866405, Example 121 ...)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643834(US11866405, Example 37)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643785(US11866405, Example 75)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643820(US11866405, Example 30 | US11866405, Example 31)
Affinity DataIC50: <0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643823(US11866405, Example 94)
Affinity DataIC50:  0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643768(US11866405, Example 4)
Affinity DataIC50: <0.300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50239559(CHEMBL4073594)
Affinity DataIC50:  0.398nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
LigandPNGBDBM50239550(CHEMBL4060741)
Affinity DataIC50:  0.398nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643849(US11866405, Example 107 | US11866405, Example 108)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643775(US11866405, Example 70)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643837(US11866405, Example 101)
Affinity DataIC50: <0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643803(US11866405, Example 84)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643821(US11866405, Example 93)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643779(US11866405, Example 72)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643854(US11866405, Example 47)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643873(US11866405, Example 119)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643763(US11866405, Example 64 | US11866405, Example 65)
Affinity DataIC50: <0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643816(US11866405, Example 28 | US11866405, Example 29)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643790(US11866405, Example 15)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643773(US11866405, Example 69)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643827(US11866405, Example 96)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643767(US11866405, Example 66 | US11866405, Example 67)
Affinity DataIC50: <0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643770(US11866405, Example 5)
Affinity DataIC50:  0.5nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50239542(CHEMBL4069417)
Affinity DataIC50:  0.501nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50239552(CHEMBL4070433)
Affinity DataIC50:  0.501nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50239549(CHEMBL4096646)
Affinity DataIC50:  0.501nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50239540(CHEMBL4086230)
Affinity DataIC50:  0.501nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643852(US11866405, Example 46)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643843(US11866405, Example 104 | US11866405, Example 109)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643868(US11866405, Example 54)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50612188(CHEMBL5283628)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of ATP by enzymatic assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM50612201(CHEMBL5270030)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of ATP by enzymatic assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643847(US11866405, Example 106)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50234161(CHEMBL4091680)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643792(US11866405, Example 16)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643796(US11866405, Example 18 | US11866405, Example 19)
Affinity DataIC50: <0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643831(US11866405, Example 98)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM643841(US11866405, Example 103)
Affinity DataIC50:  0.600nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50234157(CHEMBL4089227)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50234161(CHEMBL4091680)
Affinity DataIC50:  0.631nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
LigandPNGBDBM50234157(CHEMBL4089227)
Affinity DataIC50:  0.631nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50239551(CHEMBL4091365)
Affinity DataIC50:  0.631nMAssay Description:Inhibition of recombinant human His6-tagged PI3K p110delta/p85alpha using DiC8-PIP2 as substrate preincubated for 15 mins followed by substrate addit...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50239560(CHEMBL4081062)
Affinity DataIC50:  0.631nMAssay Description:Inhibition of photolabeling of 24 kDa polypeptide in adenosine A1 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 672 total ) | Next | Last >>
Jump to: